Transition and Elan set Phase 3 trial of ELND005

Elan (NYSE:ELN) and Transition Therapeutics (TSX:TTH; NASDAQ:TTHI) have released top line results of a Phase 2 clinical trial of their ELND005 drug in patients with mild to moderate Alzheimer’s disease and ”based on a preponderance of evidence, and input from experts in this field, the companies intend to advance ELND005 into Phase 3 studies.” Last December, [...]

Cormark ups Transition price target 52%

Cormark Securities raised its target price on “buy-rated” Transition Therapeutics (TSX:TTH; NASDAQ:TTHI) to $8 from $5.25, saying it believes Irish partner Elan is likely to move Transition’s ELND005 drug forward into a Phase 3 clinical trial in Alzheimer’s disease.  The stock closed at $3.50 on the TSX Friday. An imbalance of deaths in an ongoing [...]